[an error occurred while processing this directive]
|CANCER & TREATMENTS FOR CANCER CENTER PATIENTS PREVENTION & RISK ASSESSMENT CLINICAL TRIALS & RESEARCH LIVING WITH CANCER|
Please note: This article is part of the Cancer Center's News Archive and is here for historical purposes. The information and links may no longer be up-to-date.
Researchers unravel protein's role in lymphoma--added 1/13/09
Ann Arbor, MI. -- Using cancer cells that were originally isolated from an anaplastic large cell lymphoma patient, two researchers from the University of Michigan Comprehensive Cancer Center have identified a novel regulatory mechanism in inflammatory signaling of immune cells that may prove beneficial in treating the disease.
Their study was published in the Jan. 9 issue of Science.
The researchers wanted to better understand how the membrane protein, CD30, contributes to lymphoma. CD30 is a cell surface receptor that communicates signals from the extracellular environment into the cell resulting in a cellular response. It has been recognized since the early 1980s that CD30 is present in very high amounts in certain lymphomas and leukemias - much more than in normal cells.
"This makes CD30 an attractive therapeutic target," says study author Casey Wright, Ph.D., who conducted the research while at U-M. Wright is now an assistant professor of pharmacy at the University of Texas at Austin.
In the study, the researchers uncovered an unexpected partner protein that interacts with CD30. This protein, known as ARNT, is best characterized for its role in mediating the metabolism of environmental toxins and also for mounting the hypoxic response in cells exposed to low oxygen levels.
"Our research describes a novel role for ARNT, which had never been implicated in the signaling pathway of a membrane protein like CD30," says Wright, who conducted the study as a research fellow at the University of Michigan Medical School. His co-author is Colin Duckett, Ph.D., associate professor of molecular medicine and genetics and of pathology at the U-M Medical School.
In some lymphomas, like Hodgkin's lymphoma, the increased presence of CD30 results in a continual activation of five cellular proteins that are collectively referred to as nuclear factor-kappaB (NF- B). "NF- B turns on genes whose products are involved in cellular proliferation and, thus, sustained NF- B activity is thought to lead to cancer," Wright says.
The researchers also found that ARNT is a negative regulator of CD30 signaling in that it shuts down NF- B at the DNA level. "This is an important finding because how NF- B is regulated at the level of DNA is less clear," says Wright.
"The regulation of NF- B by ARNT provides a link between human exposures to environmental toxins and the subsequent cancers of the immune system, like lymphoma, that often arise," he says. "While these findings are significant, this is only the beginning, and there is much more work to be done before we realize the full impact of our results."
Written by Nicole Fawcett
Additional contact: Nancy Neff, University of Texas at Austin, 512-471-6504 or E-mail: firstname.lastname@example.org.
|[an error occurred while processing this directive]|